Reviewing Cancer Genetics (CGIX) and PotNetwork (POTN)

Cancer Genetics (NASDAQ:CGIX) and PotNetwork (OTCMKTS:POTN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership.

Profitability

This table compares Cancer Genetics and PotNetwork’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cancer Genetics -87.08% -121.10% -49.36%
PotNetwork N/A N/A N/A

Institutional and Insider Ownership

14.8% of Cancer Genetics shares are owned by institutional investors. Comparatively, 0.0% of PotNetwork shares are owned by institutional investors. 21.3% of Cancer Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Cancer Genetics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, PotNetwork has a beta of 10.75, meaning that its share price is 975% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Cancer Genetics and PotNetwork, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cancer Genetics 0 2 1 0 2.33
PotNetwork 0 0 0 0 N/A

Cancer Genetics presently has a consensus target price of $4.50, indicating a potential upside of 1,983.33%. Given Cancer Genetics’ higher possible upside, equities analysts clearly believe Cancer Genetics is more favorable than PotNetwork.

Earnings and Valuation

This table compares Cancer Genetics and PotNetwork’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cancer Genetics $29.12 million 0.21 -$20.88 million ($0.79) -0.27
PotNetwork N/A N/A N/A N/A N/A

PotNetwork has lower revenue, but higher earnings than Cancer Genetics.

Summary

Cancer Genetics beats PotNetwork on 5 of the 9 factors compared between the two stocks.

About Cancer Genetics

Cancer Genetics, Inc. engages in the development, commercialization, and sale of molecular and biomarker-based tests and services. Through its Select One Clinical Trials program, the firm provides a range of clinical trial services for both oncology and non-oncology genetic testing such as bioinformatics, biomaker solutions, biorepository solutions, consulting, cytogenetics testing, nucleic acid extraction and purification, flow cytometry, Focus::NGS Panel, gene expression analyses, genotyping, and pharmacogenomics. The company was founded by Raju S. K. Chaganti on April 8, 1999 and is headquartered in Rutherford, NJ.

About PotNetwork

PotNetwork Holdings, Inc, through its subsidiary, First Capital Venture Co., engages in the research, development, and sale of hemp-derived CBD oil products. It also engages in the pre-owned auto dealership business. The company sells its products through distributors and resellers, as well as through its Website. The company was formerly known as SND Auto Group Inc. and changed its name to PotNetwork Holdings, Inc in March 2017. PotNetwork Holdings, Inc is based in Fort Lauderdale, Florida.

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply